Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 6, 2000, Pages 701-708

  Ohning, G V ^a   Barbuti, R C ^a   Kovacs, T O G ^a   Sytnik, B ^a   Humphries, T J ^b   Walsh, J H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTOPEPTONE; BENZIMIDAZOLE; CARBON 14; GASTRIN; PEPTONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; UREA;

ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTRIN BLOOD LEVEL; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH PH; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTONES;

EID: 0034129392     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00774.x     Document Type: Article

References (13)

1. 1 Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
2. 2 Martínek J, Blum AL, Stolte M, et al. Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 27-34.
3. 3 Smout AJPM. Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent? Scand J Gastroenterol 1998; 225(Suppl. 225): 32-5.
4. 4 Maxwell V, Eysselein VE, Kleibeuker J, Reedy T, Walsh JH. Glucose perfusion intragastric titration. Dig Dis Sci 1984; 29: 321-6.
5. 5 Eysselein VE, Kovacs TOG, Kleibeuker JH, Maxwell V, Reedy T, Walsh JH. Regulation of gastric acid secretion by gastrin in duodenal ulcer patients and healthy subjects. Gastroenterology 1992; 102: 1142-8.
6. 6 Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
7. 7 Fujisaki H, Shibata H, Oketani K, et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 1991; 42: 321-8.
8. 8 Tomiyama Y, Morii M, Takeguchi N. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem Pharmacol 1994; 48: 2049-55.
9. 9 Lew EA, Barbuti RC, Kovacs TOG, Sytnic B, Humphries TJ, Walsh JH. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther 1998; 12: 667-72.
10. 10 Gillen D, Wirz AA, Neithercut WD, Ardill JE. McColl KEL. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999; 44: 468-75.
11. 11 Verdú EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
12. 12 Verdú EF, Armstrong D, Idstrom JP, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995; 37: 743-8.
13. 13 McColl KEL, El-Omar E, Gillen D. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull 1998; 54: 121-38.